Among more than 5,000 patients followed for a median of roughly 8 years, bilateral risk-reducing mastectomy (RRM) was ...

AstraZeneca and MSD's PARP inhibitor Lynparza has improved long-term survival when given as adjuvant therapy for early breast ...

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast, according to 6-year data from the OlympiA trial.

The benefit of the PARP inhibitor in patients with germline BRCA pathogenic variants remains evident 10 years after the first ...

Women who underwent bilateral mastectomy or removal of ovaries and Fallopian tubes had lower rates of recurrence, ovarian ...

After a median follow-up of 6.1 years, patients treated with Lynparza continued to show significant improvements in survival ...

The Institute of Cancer Research, London, is the second-ranked academic research centre in the UK - according to the Times Higher Education league table of university research quality and impact ...

Me, a major company providing direct-to-consumer genetic testing, has been struggling financially since late 2023. In ...

B reast cancer is not a single disease but multiple ones, each carrying varying degrees of risk for endangering women’s ...

Metastatic breast cancer diagnoses are rising in U.S. women, especially in younger age groups and racial minorities, as ...

DCIS, known as stage 0 breast cancer, affect the cells lining the milk ducts but has not spread outside the breast.

Women with a type of low-risk cancer might not have to rush aggressive treatment, doctors say.